US And Japan Cause A Slip In Value-Added Market
Difficulties in the US and Japan have stalled growth in the global value-added medicines market. But a coming wave of digital therapeutics promises to revive the market.
You may also be interested in...
An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.
A differentiated offering that includes biosimilars, value-added medicines and digital health technologies is central to Sandoz’ mission to improve both patient health and its own profit margins, according to CEO Richard Francis.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.